The FDA has proposed a rule to simplify how drug factories are registered, targeting the establishment-registration process for manufacturers supplying the U.S. market. The agency said the update is meant to reduce administrative friction while strengthening the drug supply chain. The proposal comes alongside ongoing efforts to streamline distributed manufacturing oversight and maintain clarity on regulatory expectations for facilities producing drugs for U.S. patients. For sponsors and contract manufacturers, any change to registration mechanics can affect timelines for product supply readiness and lifecycle compliance. Separately, regulatory content also points to evolving FDA transparency practices via the publication of drug rejection letters, highlighting continued movement on process and documentation. Together, the items underscore the FDA’s focus on operational efficiency and information flow in drug development.